Skip to content

Clinical study on Fuzheng Quxie prescription combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer

Clinical study on Fuzheng Quxie prescription combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003711
Enrollment
Unknown
Registered
2020-08-25
Start date
2021-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Sponsors

Shanghai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A total of 136 patients with lung cancer were hospitalized in the Department of Oncology, Shanghai traditional Chinese Medicine Hospital from October 2021 to May 2023. (1) all cases were confirmed by pathology or cytology as stage III b and IV non-small cell lung cancer (NSCLC). (2) less than 75 years of age. (3) the estimated survival time is more than 3 months. (4) General condition PS <= 2. (5) have the indication of chemotherapy. (6) stop using other anticancer drugs for more than one month before being selected for observation; patients who have been ineffective in the third-line treatment of western medicine before. (7) the patient has good knowledge and compliance. The lung cancer staging standard adopts the revised international staging of lung cancer published by the International Federation for Lung Cancer Research (International Association for the Study of Lung Cancer, IASLC) in 2007.

Exclusion criteria

Exclusion criteria: (1) Failure to take drugs in accordance with the regulations. (2) Those who are unable to judge the curative effect, or whose data are incomplete and affect the judgment of the curative effect. (3) Patients with severe impairment of heart, liver and kidney function. (4) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Survival period;TCM syndrome;Quality of life score;Evaluation standard of curative effect of solid tumor;Pain score;

Countries

China

Contacts

Public ContactFang Zhihong

Shanghai Traditional Chinese Medicine Hospital

ffwf2001@126.com+86 18116070351

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026